Retinal toxicities of cancer therapy drugs: Biologics, small molecule inhibitors, and chemotherapies

Retina

Volumn 34, Issue 7, 2014, Pages 1261-1280

  Liu, Catherine Y ^a   Francis, Jasmine H ^b   Brodie, Scott E ^b,c   Marr, Brian ^b   Pulido, Jose S ^d   Marmor, Michael F ^e   Abramson, David H ^b,f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d MAYO CLINIC   (United States)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

cancer; chemotherapy; drug toxicity; monoclonal antibody; retina; retinal toxicities; side effects; tyrosine kinase inhibitors

Indexed keywords

ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT; BIOLOGIC AGENT; CARBOPLATIN; CARMUSTINE; CHEMOTHERAPY AGENT; CISPLATIN; CRIZOTINIB; CYTARABINE; DABRAFENIB; DENILEUKIN DIFTITOX; FLUDARABINE; IMATINIB; INTERFERON; IPILIMUMAB; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOTANE; MSC 1936369; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; NITROSOUREA; OXALIPLATIN; PLATINUM DERIVATIVE; PROCARBAZINE; RETINOIC ACID DERIVATIVE; SMALL MOLECULE INHIBITOR; TRAMETINIB; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VEMURAFENIB; ENZYME INHIBITOR; MONOCLONAL ANTIBODY; PROTEIN TYROSINE KINASE;

CANCER CHEMOTHERAPY; CANCER THERAPY; DARK ADAPTATION; EYE TOXICITY; HUMAN; MEDLINE; PAPILLEDEMA; RETINA BLOOD VESSEL OCCLUSION; RETINA DETACHMENT; RETINA ISCHEMIA; RETINA MACULA CYSTOID EDEMA; RETINA MACULA EDEMA; RETINAL TOXICITIES; RETINOPATHY; REVIEW; SIDE EFFECT; UVEITIS; VIRUS ONCOGENE; VOGT KOYANAGI SYNDROME; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; DRUG EFFECTS; RETINA; RETINA DISEASE; TOXICITY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ENZYME INHIBITORS; HUMANS; PROTEIN-TYROSINE KINASES; RETINA; RETINAL DISEASES;

EID: 84903136232     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0000000000000242     Document Type: Review

References (144)

1. Society AC. Cancer Statistics 2013: a presentation from the American Cancer Society. 2013. Available at: http://www. cancer.org/acs/groups/content/ @epidemiologysurveilance/ documents/document/acspc-037389.pptx.
2. Network NCC. Breast Cancer. 2013. Available at: http:// www.nccn.org/professionals/physician-gls/pdf/breast.pdf.
3. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993;328: 1002-1006.
4. Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med 1998;339: 900-905.
5. Gerber DE. Targeted therapies: a new generation of cancer treatments. Am Fam Physician 2008;77: 311-319.
6. Schmid KE, Kornek GV, Scheithauer W, Binder S. Update on ocular complications of systemic cancer chemotherapy. Surv Ophthalmol 2006;51: 19-40.
7. Hazin R, Abuzetun JY, Daoud YJ, Abu-Khalaf MM. Ocular complications of cancer therapy: a primer for the ophthalmologist treating cancer patients. Curr Opin Ophthalmol 2009;20: 308-317.
8. O AE, O CE. Ocular toxicity of systemic anticancer chemotherapy. Pharm Pract 2006;4: 55-59.
9. Esmaeli B, Koller C, Papadopoulos N, Romaguera J. Interferon- induced retinopathy in asymptomatic cancer patients. Ophthalmology 2001;108: 858-860.
10. Hejny C, Sternberg P, Lawson DH, et al. Retinopathy associated with high-dose interferon alfa-2b therapy. Am J Ophthalmol 2001;131: 782-787.
11. Guyer DR, Tiedeman J, Yannuzzi LA, et al. Interferon-associated retinopathy. Arch Ophthalmol 1993;111: 350-356.
12. Ruddle JB, Harper CA, Honemann D, et al. A denileukin diftitox (Ontak) associated retinopathy? Br J Ophthalmol 2006;90: 1070-1071.
13. Ruddle JB, Prince HM. Denileukin diftitox and vision loss. Leuk Lymphoma 2007;48: 655-656.
14. Modjtahedi BS, Maibach H, Park S. Multifocal bilateral choroidal neovascularization in a patient on ipilimumab for metastatic melanoma. Cutan Ocul Toxicol 2013.
15. Wong R, Lee J, Huang J. Bilateral drug (ipilimumab)-induced vitritis, choroiditis, and serous retinal detachments suggestive of Vogt-Koyanagi-Harada syndrome. Retin Cases Brief Rep 2012;6: 423-426.
16. Saleh M, Bourcier T, Noel G, et al. Bilateral macular ischemia and severe visual loss following trastuzumab therapy. Acta Oncol 2011;50: 477-478.
17. Davar D, Tarhini AA, Kirkwood JM. Adjuvant therapy for melanoma. Cancer J 2012;18: 192-202.
18. Jain K, Lam WC, Waheeb S, et al. Retinopathy in chronic hepatitis C patients during interferon treatment with ribavirin. Br J Ophthalmol 2001;85: 1171-1173.
19. Malik NN, Sheth HG, Ackerman N, et al. A prospective study of change in visual function in patients treated with pegylated interferon alpha for hepatitis C in the UK. Br J Ophthalmol 2008;92: 256-258.
20. Cuthbertson FM, Davies M, McKibbin M. Is screening for interferon retinopathy in hepatitis C justified? Br J Ophthalmol 2004;88: 1518-1520.
21. Kim ET, Kim LH, Lee JI, Chin HS. Retinopathy in hepatitis C patients due to combination therapy with pegylated interferon and ribavirin. Jpn Journal Ophthalmology 2009;53: 598-602.
22. Lim JW, Shin MC. Pegylated-interferon-associated retinopathy in chronic hepatitis patients. Ophthalmologica 2010;224: 224-229.
23. Hayasaka S, Nagaki Y, Matsumoto M, Sato S. Interferon associated retinopathy. Br J Ophthalmol 1998;82: 323-325.
24. Zegans ME, Anninger W, Chapman C, Gordon SR. Ocular manifestations of hepatitis C virus infection. Curr Opin Ophthalmol 2002;13: 423-427.
25. Nicolo M, Artioli S, La Mattina GC, et al. Branch retinal artery occlusion combined with branch retinal vein occlusion in a patient with hepatitis C treated with interferon and ribavirin. Eur J Ophthalmol 2005;15: 811-814.
26. Kiratli H, Irkec M. Presumed interferon-associated bilateral macular arterial branch obstruction. Eye (Lond) 2000;14: 920-922.
27. Kargi SH, Oz O, Ustundag Y, Firat E. Epiretinal membrane development during interferon treatment. Can J Ophthalmol 2003;38: 610-612.
28. Schulman JA, Liang C, Kooragayala LM, King J. Posterior segment complications in patients with hepatitis C treated with interferon and ribavirin. Ophthalmology 2003;110: 437-442.
29. Kang HY, Shin MC. Pegylated interferon-associated severe retinopathy in a patient with chronic hepatitis. Korean journal of ophthalmology. Korean J Ophthalmol 2012;26: 147-150.
30. Tu KL, Bowyer J, Schofield K, Harding S. Severe interferon associated retinopathy. Br J Ophthalmol 2003;87: 247-248.
31. Nagaoka T, Sato E, Takahashi A, et al. Retinal circulatory changes associated with interferon-induced retinopathy in patients with hepatitis C. Invest Ophthalmol Vis Sci 2007;48: 368-375.
32. Nishiwaki H, Ogura Y, Miyamoto K, et al. Interferon alfa induces leukocyte capillary trapping in rat retinal microcirculation. Arch Ophthalmol 1996;114: 726-730.
33. Takeuchi M, Keino H, Kezuka T, et al. Immune responses to retinal self-antigens in CD25(+)CD4(+) regulatory T-celldepleted mice. Invest Ophthalmol Vis Sci 2004;45:1879- 1886. (Pubitemid 38868985)
34. Lemech C, Arkenau HT. Novel treatments for metastatic cutaneous melanoma and the management of emergent toxicities. Clin Med Insights Oncol 2012;6: 53-66.
35. Attia P, Phan GQ, Maker AV, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 2005;23: 6043-6053.
36. Ho WL, Wong H, Yau T. The ophthalmological complications of targeted agents in cancer therapy: what do we need to know as ophthalmologists? Acta Ophthalmol 2012.
37. Atwal JK, Chen Y, Chiu C, et al. A therapeutic antibody targeting BACE1 inhibits amyloid-beta production in vivo. Sci Transl Med 2011;3:84ra43.
38. Khan AB, D'Souza BJ, Wharam MD, et al. Cisplatin therapy in recurrent childhood brain tumors. Cancer Treat Rep 1982; 66: 2013-2020.
39. Diamond SB, Rudolph SH, Lubicz SS, et al. Cerebral blindness in association with cis-platinum chemotherapy for advanced carcinoma of the fallopian tube. Obstet Gynecol 1982;59:84S-86S. (Pubitemid 12107299)
40. AR S, E C, P M, et al. Nongranulomatous Anterior and Intermediate Uveitis secondary to selective BRAF mutation inhibitor treatment for metastatic cutaneous melanoma: a clinical case Series. Submitted 2013.
41. Houede N, Faivre SJ, Awada A. Safety and evidence of activity of MSC1936369, an oral MEK 1/2 inhibitor, in patients with advanced malignancies. J Clin Oncol 2011;29 (suppl); abstr 3019.
42. LoRusso PM, Krishnamurthi SS, Rinehart JJ, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers. Clin Cancer Res 2010;16: 1924-1937.
43. Lorusso PM, Krishnamarthi SS, Rinehard JJ. A phase 1-2 clinical study of a second generation oral MEK inhibitor, PD 0325901, in patients with advanced cancer. J Clin Oncol 2005;23:3011.
44. Martinez-Garcia M, Banerji U, Albanell J, et al. First-in-Human, phase I dose-escalation study of the safety, Pharmacokinetics, and Pharmacodynamics of RO5126766, a first-in-Class Dual MEK/RAF inhibitor in patients with Solid tumors. Clin Cancer Res 2012;18: 4806-4819.
45. Infante JR, Fecher LA, Falchook GS, et al. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Lancet Oncol 2012;13: 773-781.
46. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363: 1693-1703.
47. Labs P. XALKORI (crizotinib) prescribing information. New York, NY: 2011.
48. Breccia M, Gentilini F, Cannella L, et al. Ocular side effects in chronic myeloid leukemia patients treated with imatinib. Leuk Res 2008;32: 1022-1025.
49. Fraunfelder FW, Solomon J, Druker BJ, et al. Ocular sideeffects associated with imatinib mesylate (Gleevec). J Ocul Pharmacol The 2003;19: 371-375.
50. Christoforidis JB, DeAngelo DJ, D'Amico DJ. Resolution of leukemic retinopathy following treatment with imatinib mesylate for chronic myelogenous leukemia. Am J Ophthalmol 2003;135: 398-400.
51. Gulati AP, Saif MW. Retinal neovascularization and hemorrhage associated with the use of imatinib (Gleevec((R))) in a patient being treated for gastrointestinal stromal tumor (GIST). Anticancer Res 2012;32: 1375-1377.
52. Masood I, Negi A, Dua HS. Imatinib as a cause of cystoid macular edema following uneventful phacoemulsification surgery. J Cataract Refract Surg 2005;31: 2427-2428.
53. Georgalas I, Pavesio C, Ezra E. Bilateral cystoid macular edema in a patient with chronic myeloid leukaemia under treatment with imanitib mesylate: report of an unusual side effect. Graefes Arch Clin Exp Ophthalmol 2007;245: 1585-1586.
54. Kusumi E, Arakawa A, Kami M, et al. Visual disturbance due to retinal edema as a complication of imatinib. Leukemia 2004;18: 1138-1139.
55. DeLuca C, Shenouda-Awad N, Haskes C, Wrzesinski S. Imatinib mesylate (Gleevec) induced unilateral optic disc edema. Optom Vis Sci 2012;89:e16-e22.
56. Kwon SI, Lee DH, Kim YJ. Optic disc edema as a possible complication of Imatinib mesylate (Gleevec). Jpn J Ophthalmol 2008;52: 331-333.
57. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364: 2507-2516.
58. Platz A, Egyhazi S, Ringborg U, Hansson J. Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site. Mol Oncol 2008;1: 395-405.
59. Lorusso PM, Adjei AA, Varterasian M, et al. Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol 2005; 23: 5281-5293.
60. Haura EB, Ricart AD, Larson TG, et al. A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer. Clin Cancer Res 2010;16: 2450-2457.
61. NCT01245062 CgI. Accessed August 1, 2013.
62. Kitzmann AS, Baratz KH, Mohney BG, et al. Histologic studies of the intraocular toxicity of imatinib mesylate in rabbits. Eye (Lond) 2008;22: 712-714.
63. Biswas SK, Zhao Y, Sandirasegarane L. Imatinib induces apoptosis by inhibiting PDGF- but not insulin-induced PI 3- kinase/Akt survival signaling in RGC-5 retinal ganglion cells. Mol Vis 2009;15: 1599-1610.
64. Sigma-Tau. Matulane ®(procarbazine hydrochloride) capsules prescribing information; 2004.
65. Kupersmith MJ, Frohman LP, Choi IS, et al. Visual system toxicity following intra-arterial chemotherapy. Neurology 1988;38: 284-289.
66. Greenberg HS, Ensminger WD, Seeger JF, et al. Intra-arterial BCNU chemotherapy for the treatment of malignant gliomas of the central nervous system: a preliminary report. Cancer Treat Rep 1981;65: 803-810.
67. Greenberg HS, Ensminger WD, Chandler WF, et al. Intraarterial BCNU chemotherapy for treatment of malignant gliomas of the central nervous system. J Neurosurg 1984;61: 423-429.
68. Grimson BS, Mahaley MS Jr, Dubey HD, Dudka L. Ophthalmic and central nervous system complications following intracarotid BCNU (Carmustine). J Clin Neuroophthalmol 1981;1: 261-264.
69. Pickrell L, Purvin V. Ischemic optic neuropathy secondary to intracarotid infusion of BCNU. J Clin Neuroophthalmol 1987;7: 87-92.
70. Shingleton BJ, Bienfang DC, Albert DM, et al. Ocular toxicity associated with high-dose carmustine. Arch Ophthalmol 1982;100: 1766-1772.
71. Shapiro WR. Chemotherapy of malignant gliomas: studies of the BTCG. Rev Neurol (Paris) 1992;148: 428-434.
72. Bristol-Myers Squibb. BiCNU - (Carmustine for Injection) Prescribing Information. Princeton, NJ: Bristol-Myers Squibb; 2003.
73. Johnson DW, Cagnoni PJ, Schossau TM, et al. Optic disc and retinal microvasculopathy after highdose chemotherapy and autologous hematopoietic progenitor cell support. Bone Marrow Transplant 1999;24: 785-792.
74. Khawly JA, Rubin P, Petros W, et al. Retinopathy and optic neuropathy in bone marrow transplantation for breast cancer. Ophthalmology 1996;103: 87-95.
75. Wang MY, Arnold AC, Vinters HV, Glasgow BJ. Bilateral blindness and lumbosacral myelopathy associated with highdose carmustine and cisplatin therapy. Am J Ophthalmol 2000;130: 367-368.
76. Lauer AK, Wobig JL, Shults WT, et al. Severe ocular and orbital toxicity after intracarotid etoposide phosphate and carboplatin therapy. Am J Ophthalmol 1999;127: 230-233.
77. Watanabe W, Kuwabara R, Nakahara T, et al. Severe ocular and orbital toxicity after intracarotid injection of carboplatin for recurrent glioblastomas. Graefes Arch Clin Exp Ophthalmol 2002;240: 1033-1035.
78. Rankin EM, Pitts JF. Ophthalmic toxicity during carboplatin therapy. Annals of oncology. Ann Oncol 1993;4: 337-338.
79. Dropcho EJ, Rosenfeld SS, Vitek J, et al. Phase II study of intracarotid or selective intracerebral infusion of cisplatin for treatment of recurrent anaplastic gliomas. J Neurooncol 1998; 36: 191-198.
80. Margo CE, Murtagh FR. Ocular and orbital toxicity after intracarotid cisplatin therapy. Am J Ophthalmol 1993;116: 508-509.
81. Wu HM, Lee AG, Lehane DE, et al. Ocular and orbital complications of intraarterial cisplatin. A case report. J Neuroophthalmol 1997;17: 195-198.
82. Rogers LR, Purvis JB, Lederman RJ, et al. Alternating sequential intracarotid BCNU and cisplatin in recurrent malignant glioma. Cancer 1991;68: 15-21.
83. Kwan AS, Sahu A, Palexes G. Retinal ischemia with neovascularization in cisplatin related retinal toxicity. Am J Ophthalmol 2006;141: 196-197.
84. Kupersmith MJ, Seiple WH, Holopigian K, et al. Maculopathy caused by intra-arterially administered cisplatin and intravenously administered carmustine. Am J Ophthalmol 1992;113: 435-438.
85. Hilliard LM, Berkow RL, Watterson J, et al. Retinal toxicity associated with cisplatin and etoposide in pediatric patients. Med Pediatr Oncol 1997;28: 310-313.
86. Wilding G, Caruso R, Lawrence TS, et al. Retinal toxicity after high-dose cisplatin therapy. J Clin Oncol 1985;3:1683- 1689. (Pubitemid 16199221)
87. Feun LG, Wallace S, Stewart DJ, et al. Intracarotid infusion of cis-diamminedichloroplatinum in the treatment of recurrent malignant brain tumors. Cancer 1984;54: 794-799.
88. Miller DF, Bay JW, Lederman RJ, et al. Ocular and orbital toxicity following intracarotid injection of BCNU (carmustine) and cisplatinum for malignant gliomas. Ophthalmology 1985;92: 402-406.
89. Marmor MF. Negative-type electroretinogram from cisplatin toxicity. Doc Ophthalmol 1993;84: 237-246.
90. Squibb B-M. Platinol ®-AQ (Cisplatin Injection) Prescribing Information. Princeton, NJ: Bristol-Myers Squibb; 2002.
91. Gilbar P, Sorour N. Retinal vein thrombosis in a patient with metastatic colon cancer receiving XELOX chemotherapy combined with bevacizumab pre-hepatic resection. J Oncol Pharm Pract 2012;18: 152-154.
92. Millay RH, Klein ML, Shults WT, et al. Maculopathy associated with combination chemotherapy and osmotic opening of the blood-brain barrier. Am J Ophthalmol 1986;102: 626-632.
93. Bishop RJ, Ding X, Heller CK 3rd, et al. Rapid vision loss associated with fludarabine administration. Retina 2010;30: 1272-1277.
94. Parke Davis. Nipent ®(pentostatin for injection) prescribing information. Morris Plains, NJ: Parke Davis, 1991.
95. Bedford Laboratories. Pentostatin for injection prescribing information. Bedford, OH: Bedford Laboratories; 2006.
96. Vogler WR, Winton EF, Heffner LT, et al. Ophthalmological and other toxicities related to cytosine arabinoside and total body irradiation as preparative regimen for bone marrow transplantation. Bone Marrow Transplant 1990;6: 405-409.
97. Wiznia RA, Rose A, Levy AL. Occlusive microvascular retinopathy with optic disc and retinal neovascularization in acute lymphocytic leukemia. Retina 1994;14: 253-255.
98. Telander DG, Sarraf D. Cystoid macular edema with docetaxel chemotherapy and the fluid retention syndrome. Semin Ophthalmol 2007;22: 151-153.
99. Teitelbaum BA, Tresley DJ. Cystic maculopathy with normal capillary permeability secondary to docetaxel. Optom Vis Sci 2003;80: 277-279.
100. Georgakopoulos CD, Makri OE, Vasilakis P, Exarchou A. Angiographically silent cystoid macular oedema secondary to paclitaxel therapy. Clinical & experimental optometry. Clin Exp Optom 2012;95: 233-236.
101. Smith SV, Benz MS, Brown DM. Cystoid macular edema secondary to albumin-bound paclitaxel therapy. Arch Ophthalmol 2008;126: 1605-1606.
102. Joshi MM, Garretson BR. Paclitaxel maculopathy. Arch Ophthalmol 2007;125: 709-710.
103. Murphy CG, Walsh JB, Hudis CA, et al. Cystoid macular edema secondary to nab-paclitaxel therapy. J Clin Oncol 2010;28:e684-e687.
104. Risard SM, Pieramici DJ, Rabena MD. Cystoid macular oedema secondary to paclitaxel (Abraxane). Retin Cases Brief Rep 2009;3: 383-385.
105. Tan WW, Walsh T. Ocular toxicity secondary to paclitaxel in two lung cancer patients. Med Pediatr Oncol 1998;31:177. (Pubitemid 28387918)
106. Hoffman DL, Mattox VR. Treatment of adrenocortical carcinoma with o,p'-DDD. Med Clin North Am 1972;56:999- 1012.
107. Hutter AM Jr, Kayhoe DE. Adrenal cortical carcinoma. Results of treatment with o,p'DDD in 138 patients. Am J Med 1966;41: 581-592.
108. Molnar GD, Mattox VR, Bahn RC. Observations in adrenal cancer. A report on 7 patients treated with o'pDDD. Cancer 1963;16:259.
109. Ng WT, Toohey MG, Mulhall L, Mackey DA. Pigmentary retinopathy, macular oedema, and abnormal ERG with mitotane treatment. Br J Ophthalmol 2003;87: 500-501.
110. Abu el-Asrar AM, al-Momen AK, Harakati MS. Terson's syndrome in a patient with acute promyelocytic leukemia on alltrans retinoic acid treatment. Doc Ophthalmol 1993;84: 373-378.
111. Guirgis MF, Lueder GT. Intracranial hypertension secondary to all-trans retinoic acid treatment for leukemia: diagnosis and management. J AAPOS 2003;7: 432-434.
112. Bourla DH, Sarraf D, Schwartz SD. Peripheral retinopathy and maculopathy in high-dose tamoxifen therapy. Am Journal Ophthalmol 2007;144: 126-128.
113. Kaiser-Kupfer MI, Kupfer C, Rodrigues MM. Tamoxifen retinopathy. A clinicopathologic report. Ophthalmology 1981; 88: 89-93.
114. McKeown CA, Swartz M, Blom J, Maggiano JM. Tamoxifen retinopathy. Br J Ophthalmol 1981;65: 177-179.
115. Kaiser-Kupfer MI, Lippman ME. Tamoxifen retinopathy. Cancer Treat Reports 1978;62: 315-320.
116. Curtis MG. Comparative tolerability of first-generation selective estrogen receptor modulators in breast cancer treatment and prevention. Drug Saf 2001;24: 1039-1053.
117. Gorin MB, Day R, Costantino JP, et al. Long-term tamoxifen citrate use and potential ocular toxicity. Am J Ophthalmol 1998;125: 493-501.
118. Tang R, Shields J, Schiffman J, et al. Retinal changes associated with tamoxifen treatment for breast cancer. Eye (Lond) 1997;11: 295-297.
119. Nayfield SG, Gorin MB. Tamoxifen-associated eye disease. A review. J Clin Oncol 1996;14: 1018-1026.
120. Pavlidis NA, Petris C, Briassoulis E, et al. Clear evidence that long-term, low-dose tamoxifen treatment can induce ocular toxicity. A prospective study of 63 patients. Cancer 1992;69: 2961-2964.
121. Yanyali AC, Freund KB, Sorenson JA, et al. Tamoxifen retinopathy in a male patient. Am J Ophthalmol 2001; 131: 386-387.
122. Ashford AR, Donev I, Tiwari RP, Garrett TJ. Reversible ocular toxicity related to tamoxifen therapy. Cancer 1988;61: 33-35.
123. Gianni L, Panzini I, Li S, et al. Ocular toxicity during adjuvant chemoendocrine therapy for early breast cancer: results from International Breast Cancer Study Group trials. Cancer 2006;106: 505-513.
124. Gualino V, Cohen SY, Delyfer MN, et al. Optical coherence tomography findings in tamoxifen retinopathy. Am J Ophthalmol 2005;140: 757-758.
125. Parkkari M, Paakkala AM, Salminen L, et al. Ocular sideeffects in breast cancer patients treated with tamoxifen and toremifene: a randomized follow-up study. Acta Ophthalmol Scand 2003;81: 495-499.
126. Ripps H, Carr RE, Siegel IM, Greenstein VC. Functional abnormalities in vincristine-induced night blindness. Invest Ophthalmol Vis Sci 1984;25: 787-794.
127. Katz BJ, Ward JH, Digre KB, et al. Persistent severe visual and electroretinographic abnormalities after intravenous Cisplatin therapy. J Neuroophthalmol 2003;23: 132-135.
128. Klemencic S. Cotton wool spots as an indicator of methotrexate- induced blood dyscrasia. Optometry 2010;81: 177-180.
129. Ponjavic V, Granse L, Stigmar EB, Andreasson S. Reduced full-field electroretinogram (ERG) in a patient treated with methotrexate. Acta Ophthalmol Scand 2004;82: 96-99.
130. Peng YM, Dalton WS, Alberts DS, et al. Pharmacokinetics of N-4-hydroxyphenyl-retinamide and the effect of its oral administration on plasma retinol concentrations in cancer patients. Int J Cancer 1989;43: 22-26.
131. Rodeghiero F, Avvisati G, Castaman G, et al. Early deaths and anti-hemorrhagic treatments in acute promyelocytic leukemia. A GIMEMA retrospective study in 268 consecutive patients. Blood 1990;75: 2112-2117.
132. Miller WH Jr, Kakizuka A, Frankel SR, et al. Reverse transcription polymerase chain reaction for the rearranged retinoic acid receptor alpha clarifies diagnosis and detects minimal residual disease in acute promyelocytic leukemia. Proc Natl Acad Sci U S A 1992;89: 2694-2698.
133. Burnett AK, Grimwade D, Solomon E, et al. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with alltrans retinoic acid: result of the Randomized MRC Trial. Blood 1999;93: 4131-4143.
134. Modiano MR, DaltonWS, Lippman SM, et al. Phase II study of fenretinide (N-[4-hydroxyphenyl]retinamide) in advanced breast cancer and melanoma. Invest New Drugs 1990;8: 317-319.
135. Kaiser-Kupfer MI, Peck GL, Caruso RC, et al. Abnormal retinal function associated with fenretinide, a synthetic retinoid. Arch Ophthalmol 1986;104: 69-70.
136. Costa A, Malone W, Perloff M, et al. Tolerability of the synthetic retinoid Fenretinide (HPR). Eur J Cancer Clin Oncol 1989;25: 805-808.
137. Marmor MF, Jain A, Moshfeghi D. Total rod ERG suppression with high dose compassionate Fenretinide usage. Doc Ophthalmol 2008;117: 257-261.
138. Weleber RG, Denman ST, Hanifin JM, Cunningham WJ. Abnormal retinal function associated with isotretinoin therapy for acne. Arch Ophthalmol 1986;104: 831-837.
139. Denman S,Weleber R, Hanifin JM, et al. Abnormal night vision and altered dark adaptometry in patients treated with isotretinoin for acne. J Am Acad Dermatol 1986;14: 692-693.
140. Brown RD, Grattan CE. Visual toxicity of synthetic retinoids. Br J Ophthalmol 1989;73: 286-288.
141. Weisfeld-Adams JD, Dutton GN, Murphy DM. Vincristine sulfate as a possible cause of optic neuropathy. Pediatr Blood Cancer 2007;48: 238-240.
142. Shurin SB, Rekate HL, Annable W. Optic atrophy induced by vincristine. Pediatrics 1982;70: 288-291.
143. Norton SW, Stockman JA III. Unilateral optic neuropathy following vincristine chemotherapy. J Pediatr Ophthalmol Strabismus 1979;16: 190-193.
144. Sanderson PA, Kuwabara T, Cogan DG. Optic neuropathy presumably caused by vincristine therapy. Am J Ophthalmol 1976;81: 146-150.